H. Lundbeck A/S, which develops products for brain disorders, launched four new products in 2014 but the ensuing revenue was not enough to offset the effects of generic competition. Its revenue declined by 11.7%, a 2013 profit turned into a 2014 loss and the Danish company’s dividend was passed.
